Compare BIO-TECHNE Corp (TECH) vs Zillow Group Inc Class A (ZG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
BIO-TECHNE Corp vs Zillow Group Inc Class A — how do they compare? BIO-TECHNE Corp trades at $72.13 (market cap $11.24B), while Zillow Group Inc Class A trades at $34.4 (market cap $7.60B). The key difference: BIO-TECHNE Corp is the larger of the two by market cap, and BIO-TECHNE Corp pays a 0.44% dividend while Zillow Group Inc Class A pays none. Which is the better fit depends on your goals.
| TECH | ZG | |
|---|---|---|
Market Cap | $11.24B | $7.60B |
Sector | Health | Media |
52-Week High | $72.29 | $86.76 |
52-Week Low | $43.31 | $29.14 |
Enterprise Value | $11.32B | $7.48B |
Dividend Yield | 0.44% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Bio-Techne (TECH) trades at $72.29, up 0.54% today, with a bullish technical signal from moving averages and a consensus analyst price target of $71.67. Recent earnings showed mixed results, with a Q4 2025 beat but a Q1 2026 miss. The company maintains strong gross margins at 64.96% but faces declining net income margins, down to 6.01% in 2025. Positive cash flow trends and a pending acquisition by Merck highlight ongoing corporate developments.
Outlook is balanced with growth potential from product innovation and acquisition synergies, but risks include earnings volatility, high valuation multiples, and shareholder litigation over the merger terms. Institutional sentiment is split evenly between buy and hold ratings, reflecting cautious optimism amid execution challenges.
Zillow Group (ZG) trades at $33.95, up 0.56% today, with a bearish technical signal and mixed earnings history including recent beats. Revenue growth is solid at $2.58B in 2025, but high P/E of 147.61 reflects premium valuation. Negative net cash flow and a securities class action deadline on August 10, 2026, add near-term pressure.
The stock faces headwinds from legal risks and volatile cash flows, yet analyst consensus targets $46.60 with 47% buy ratings. Upside depends on sustained profitability and business model transition success, while legal outcomes and market softness pose key risks for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About BIO-TECHNE Corp
Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →About Zillow Group Inc Class A
Zillow Group is an Internet-based real estate company that has historically focused on deriving ad revenue from third-party brokers on online marketplaces such as Zillow.com, Trulia, and HotPads. More recently it has shifted its focus to iBuying via the Zillow Offers platform.
Read more on ZG →
